P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL
P1066：帕博利珠单抗单药治疗作为霍奇金淋巴瘤的一线疗法，适用于老年患者或不适合ABVD方案的患者，不排除后续治疗，并能提供足够的生存期。
期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-023-46490-5
Wilkinson, D; Gallagher, I J; McNelly, A; Bear, D E; Hart, N; Montgomery, H E; Le Guennec, A; Conte, M R; Francis, T; Harridge, S D R; Atherton, P J; Puthucheary, Z A; Dickinson, Michael; Berkahn, Leanne; Trotman, Judith; Butler, Jason; Neeson, Paul; Bressel, Matthias; Minson, Adrian
